Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Halychpharm A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.	Ukraine	GFARM
HANALL BIOPHARMA CO.,LTD Develops innovative medicines for chronic diseases through antibody and small molecule research.	South Korea	009420
Hana Pharm. Co., Ltd. Pharmaceutical firm specializing in anesthetics and narcotic analgesics for global markets.	South Korea	293480
Hanmi Pharm. Co., Ltd. Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.	South Korea	128940
Hansa Biopharma Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.	Sweden	HNSA
Harmony Biosciences Holdings, Inc. Develops innovative therapies for rare neurological diseases, focusing on conditions like narcolepsy.	United States of America	HRMY
HARROW, INC. Develops branded ophthalmic therapies and custom compounded solutions for North American eyecare.	United States of America	HROW
HCW Biologics Inc. Developing novel immunotherapies to treat aging-related chronic inflammation.	United States of America	HCWB
HEALIOS K.K. Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.	Japan	4593
Ｈｅａｒｔｓｅｅｄ株式会社 Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.	Japan	219A